PLOS ONE publishes TAG’s rigorous, peer-reviewed calculation of investments in the development of this life-saving TB medicine.

Sustained and expanded financing is needed to safeguard TB research against COVID-19–related disruptions and improve global epidemic preparedness.

The Declaration was launched in May 2019 by TBpeople in partnership with the Stop TB Partnership.

Member States of the World Health Organization adopt the Global Strategy for TB Research and Innovation at 73rd World Health Assembly.

TAG and OTMeds call on Sanofi to reverse its efforts to patent two obvious combinations of two critical drugs to prevent TB: rifapentine and isoniazid.

Treatment Action Group launches two new TB Activist Guides: An Activist’s Guide to Tuberculosis Diagnostic Tools, and An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis.

A technical brief for policymakers and program implementers - a joint effort of the Global Coalition of TB Activists, the Stop TB Partnership and the Northwestern Pritzker School of Law.

TB CAB Access Considerations Statement Regarding Johnson & Johnson Announcement of Bedaquiline Price Reduction

Bedaquiline is a public good, and must be treated as such. Johnson & Johnson once again refused to meet evidence-based demands to price bedaquiline at $1/day.

120,707 people signed petitions urging the corporation to drop the price.